Naoun Natacha, Bernard-Tessier Alice, Fizazi Karim
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.
Chemotherapy (three cycles of bleomycin + etoposide + cisplatin or four of etoposide + cisplatin) cures the vast majority of stage II seminomas. Retroperitoneal lymph node dissection (RPLND) is safe in early-stage seminoma, but the risk of relapse is not negligible. Long-term chemotherapy side effects are a reality but may be reduced using de-escalation strategies such as in the SEMITEP trial design, motivated by growing interest in survivorship. RPLND may be an option for well-informed select patients who understand that it may be associated with a higher rate of relapse than with cisplatin-based chemotherapy. In any case, local and systemic treatment should not be performed outside high-volume centers.
化疗(博来霉素+依托泊苷+顺铂三个周期或依托泊苷+顺铂四个周期)可治愈绝大多数II期精原细胞瘤。腹膜后淋巴结清扫术(RPLND)在早期精原细胞瘤中是安全的,但复发风险并非可以忽略不计。长期化疗副作用是现实存在的,但可以通过采用降阶梯策略来降低,比如在SEMITEP试验设计中,这是出于对生存质量关注度的不断提高。对于充分知情且理解RPLND可能比基于顺铂的化疗有更高复发率的特定患者,RPLND可能是一种选择。无论如何,局部和全身治疗不应在非高容量中心进行。